A Phase 4 interventional study of Ranolazine and Placebo to match ranolazine in Myocardial Perfusion Imaging and Myocardial Ischemia, sponsored by Gilead Sciences. Completed at 43 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-03.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 218 studies in Myocardial Ischemia with a site in United States — 23 open to participants now, 26 under way, none of them phase 3. Myocardial Ischemia · United States.
Among the 218 studies in Myocardial Ischemia with a site in United States, this one is the 76th largest by enrollment of the 150 interventional ones that give a count, is one of 14 that started in 2010, is one of 19 in phase 4, and was the 97th registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →23 of the 218 studies in Myocardial Ischemia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
218 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 31 · Phase 3 21 · Phase 4 19
First in 1990; this study’s year is marked. 14 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is below the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 87 across the 150 interventional studies, 205 across the 67 observational. Of the 172 that completed or were terminated, 77 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 218 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 4 studies filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Myocardial Ischemia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
| NCT06271577AliveCorSmartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II | 2026-12 |
| NCT02855554Medical University of South CarolinaQuantitative Cardiac Parametric Mapping | 2026-12 |
| NCT05788666NYU Langone HealthUse of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease | 2027-03-01 |
| NCT06047028University of Texas Southwestern Medical CenterPrognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 218 studies in Myocardial Ischemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study enrolled participants with documented exercise-induced myocardial ischemia in order to evaluate whether ranolazine, when taken prior to exercise, can improve blood flow to the heart (myocardial perfusion), as assessed by exercise-induced myocardial perfusion defect size (PDS) and total perfusion deficit (TPD), using gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI).
This was a 2-period crossover study. The last dose of each period must have been taken 3-4 hours prior to conduct of the exercise SPECT MPI. After the research exercise SPECT MPI was performed at the end of Period 1, participants discontinued the treatment they were randomized to for that period and began the other treatment in Period 2.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
Drug: Ranolazine · Drug: Placebo to match ranolazine · Procedure: SPECT MPI · Behavioral: Exercise
Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
Drug: Ranolazine · Drug: Placebo to match ranolazine · Procedure: SPECT MPI · Behavioral: Exercise
* One 500 mg tablet in the evening on Day 1 of the period * One 500 mg tablet, twice daily on Days 2-3 of the period * Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)
Also known as: Ranexa®
Placebo to match ranolazine administered in the same form and frequency as the active drug.
Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
Treadmill stress test
Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment
PDS is the amount (percent) of the myocardium with decreased blood flow. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by gated single photon emission computed tomography (SPECT) imaging following exercise at the end of the ranolazine and placebo treatment periods.
Time frame: Up to 33 days
Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment
TPD is a score that measures the overall impact of a region of decreased myocardial blood flow, incorporating both the amount and severity of the decreased flow. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging following exercise at the end of the ranolazine and placebo treatment periods.
Time frame: Up to 33 days
Perfusion Defect Severity at Baseline, End of Period 1, and End of Period 2
Perfusion defect severity was assessed for each participant as the percentage of the 17 myocardium segments with a relative perfusion defect score of 3 or 4 on a 0-4 scale. Segment scores are: 0 = normal perfusion; 1 = mild reduction in counts-not definitely abnormal; 2 = moderate reduction in counts-definitely abnormal; 3 = severe reduction in counts; 4 = absent uptake (lower scores correspond to less severity and higher scores correspond to increased severity). A lower percentage means fewer segments have severely reduced blood flow. Measurements were obtained by SPECT imaging following exercise at baseline and at the end of Periods 1 and 2.
Time frame: Up to 33 days
Exercise-induced Reversible Perfusion Defect Size (PDS) at Baseline, End of Period 1, and End of Period 2
Exercise-induced reversible PDS was derived as the exercise PDS at baseline and at the end of Periods 1 and 2 minus the resting PDS at baseline. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.
Time frame: Up to 33 days
Exercise-induced Reversible Total Perfusion Deficit (TPD) at Baseline, End of Period 1, and End of Period 2
Exercise-induced reversible TPD was derived as the exercise TPD at baseline and at the end of Periods 1 and 2 minus the resting TPD at baseline. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.
Time frame: Up to 33 days
Participants were enrolled in a total of 27 study sites in the United States, Canada, Czech Republic, and Israel. The first participant was screened on 29 September 2010. The last participant observation was on 27 September 2012.
| Milestone | Ranolazine/Placebo | Placebo/Ranolazine |
|---|---|---|
| Started | 41 | 40 |
| Completed | 39 | 38 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Consent withdrawal | 0 | 1 |
| Withdrew: Significant dosing noncompliance | 0 | 1 |
| Milestone | Ranolazine/Placebo | Placebo/Ranolazine |
|---|---|---|
| Started | 39 | 39 |
| Completed | 39 | 37 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 2 |
PDS is the amount (percent) of the myocardium with decreased blood flow. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by gated single photon emission computed tomography (SPECT) imaging following exercise at the end of the ranolazine and placebo treatment periods.
| percentage of myocardium | Ranolazine | Placebo |
|---|---|---|
| Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment | 21.54 ± 1.51 | 20.87 ± 1.51 |
TPD is a score that measures the overall impact of a region of decreased myocardial blood flow, incorporating both the amount and severity of the decreased flow. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging following exercise at the end of the ranolazine and placebo treatment periods.
| units on a scale | Ranolazine | Placebo |
|---|---|---|
| Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment | 17.23 ± 1.26 | 16.57 ± 1.26 |
Perfusion defect severity was assessed for each participant as the percentage of the 17 myocardium segments with a relative perfusion defect score of 3 or 4 on a 0-4 scale. Segment scores are: 0 = normal perfusion; 1 = mild reduction in counts-not definitely abnormal; 2 = moderate reduction in counts-definitely abnormal; 3 = severe reduction in counts; 4 = absent uptake (lower scores correspond to less severity and higher scores correspond to increased severity). A lower percentage means fewer segments have severely reduced blood flow. Measurements were obtained by SPECT imaging following exercise at baseline and at the end of Periods 1 and 2.
| percentage of segments | Ranolazine/Placebo | Placebo/Ranolazine |
|---|---|---|
| Baseline | 11.4 ± 2.0 | 8.5 ± 2.0 |
| End of Period 1 | 11.6 ± 1.9 | 10.2 ± 2.1 |
| End of Period 2 | 10.4 ± 1.9 | 9.5 ± 2.0 |
Exercise-induced reversible PDS was derived as the exercise PDS at baseline and at the end of Periods 1 and 2 minus the resting PDS at baseline. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.
| percentage of myocardium | Ranolazine/Placebo | Placebo/Ranolazine |
|---|---|---|
| Baseline exercise minus baseline resting | 12.5 ± 1.1 | 13.5 ± 1.3 |
| End of Period 1 exercise minus baseline resting | 12.7 ± 1.2 | 14.1 ± 1.4 |
| End of Period 2 exercise minus baseline resting | 12.4 ± 1.0 | 15.2 ± 1.4 |
Exercise-induced reversible TPD was derived as the exercise TPD at baseline and at the end of Periods 1 and 2 minus the resting TPD at baseline. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.
| units on a scale | Ranolazine/Placebo | Placebo/Ranolazine |
|---|---|---|
| Baseline exercise minus baseline resting | 10.5 ± 0.9 | 10.5 ± 1.0 |
| End of Period 1 exercise minus baseline resting | 10.5 ± 0.9 | 10.7 ± 1.0 |
| End of Period 2 exercise minus baseline resting | 10.1 ± 0.8 | 11.6 ± 1.1 |
Collected over Up to 33 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Onset Following Ranolazine | — | 2/80 (2.5%) | 25/80 (31.3%) |
| Onset Following Placebo | — | 0/79 (0%) | 7/79 (8.9%) |
| Onset at Any Time Following Ranolazine | — | 2/80 (2.5%) | 28/80 (35%) |
| Event | Onset Following Ranolazine | Onset Following Placebo | Onset at Any Time Following Ranolazine |
|---|---|---|---|
| BronchitisInfections and infestations | 1/80 | 0/79 | 1/80 |
| Electrocardiogram ST segment elevationInvestigations | 1/80 | 0/79 | 1/80 |
| Event | Onset Following Ranolazine | Onset Following Placebo | Onset at Any Time Following Ranolazine |
|---|---|---|---|
| DizzinessNervous system disorders | 11/80 | 0/79 | 11/80 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/80 | 2/79 | 9/80 |
| ConstipationGastrointestinal disorders | 6/80 | 1/79 | 6/80 |
| NauseaGastrointestinal disorders | 5/80 | 2/79 | 5/80 |
| Angina pectorisCardiac disorders | 3/80 | 1/79 | 4/80 |
| HeadacheNervous system disorders | 3/80 | 3/79 | 4/80 |
Safety Analysis Set
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 66 ± 9.0 |
| Age, Customized(participants) | All Participants |
|---|---|
| 18 to 39 years | 0 |
| 40 to 64 years | 29 |
| 65 to 74 years | 39 |
| ≥ 75 years | 13 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 6 |
| Male | 75 |
| Race/Ethnicity, Customized(participants) | All Participants |
|---|---|
| White | 72 |
| African-American | 5 |
| Other | 4 |
| Race/Ethnicity, Customized(participants) | All Participants |
|---|---|
| Hispanic Or Latino | 9 |
| Not Hispanic Or Latino | 62 |
| Not Reported | 5 |
| Unknown | 5 |
| Region of Enrollment(participants) | All Participants |
|---|---|
| United States | 38 |
| Czech Republic | 2 |
| Canada | 27 |
| Israel | 14 |
| Body mass index(kg/m^2) | All Participants |
|---|---|
| Mean | 29.6 ± 3.8 |
| Weight(kg) | All Participants |
|---|---|
| Mean | 88.6 ± 14.2 |
The record gives a start of Sep 2010, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 2 years after primary completion. A results delay was requested in Aug 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine